Literature DB >> 10896868

Naltrexone administered to central nucleus of amygdala or PVN: neural dissociation of diet and energy.

M J Glass1, C J Billington, A S Levine.   

Abstract

There is evidence that opioids may affect food consumption through mechanisms as diverse as reward or energy metabolism. However, these hypotheses are derived from studies employing peripheral or, more rarely, intracerebroventricular administration of drugs. Opioid receptors have a wide distribution in the central nervous system and include a number of regions implicated in food intake such as the hypothalamic paraventricular nucleus (PVN) and the central nucleus of the amygdala (ACe). It is not known whether local opioid receptor blockade in either of these regions will produce similar effects on food intake. To examine this issue, a chronic cannula was aimed at either the PVN or ACe of rats that were fed a choice of a high-fat and high-carbohydrate diet, which allows for the measurement of both preference and total energy consumption. Naltrexone influenced preferred and nonpreferred food consumption, depending on the site of administration. Consumption of both preferred and nonpreferred diets was suppressed after PVN naltrexone administration, whereas only preferred diet intake was reduced after ACe injection of naltrexone. The present evidence indicates that direct stimulation of different brain regions with naltrexone may be associated with diverse effects on diet selection, which may be accounted for by manipulation of specific functional neural circuitry.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896868     DOI: 10.1152/ajpregu.2000.279.1.R86

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  28 in total

Review 1.  Cognitive and neuronal systems underlying obesity.

Authors:  Scott E Kanoski
Journal:  Physiol Behav       Date:  2012-01-12

Review 2.  The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence.

Authors:  Michael J Glass
Journal:  Vitam Horm       Date:  2010       Impact factor: 3.421

3.  Pituitary Adenylate Cyclase-Activating Peptide in the Central Amygdala Causes Anorexia and Body Weight Loss via the Melanocortin and the TrkB Systems.

Authors:  Attilio Iemolo; Antonio Ferragud; Pietro Cottone; Valentina Sabino
Journal:  Neuropsychopharmacology       Date:  2015-02-04       Impact factor: 7.853

Review 4.  The many paths to fear.

Authors:  Cornelius T Gross; Newton Sabino Canteras
Journal:  Nat Rev Neurosci       Date:  2012-08-01       Impact factor: 34.870

5.  Maternal high-fat diet during pregnancy and lactation reduces the appetitive behavioral component in female offspring tested in a brief-access taste procedure.

Authors:  Yada Treesukosol; Bo Sun; Alexander A Moghadam; Nu-Chu Liang; Kellie L Tamashiro; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-05       Impact factor: 3.619

Review 6.  Reassessing wanting and liking in the study of mesolimbic influence on food intake.

Authors:  Saleem M Nicola
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-08-17       Impact factor: 3.619

Review 7.  Preference or fat? Revisiting opioid effects on food intake.

Authors:  Sharif A Taha
Journal:  Physiol Behav       Date:  2010-03-04

Review 8.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

9.  Which cue to "want?" Central amygdala opioid activation enhances and focuses incentive salience on a prepotent reward cue.

Authors:  Stephen V Mahler; Kent C Berridge
Journal:  J Neurosci       Date:  2009-05-20       Impact factor: 6.167

10.  Effects of naltrexone and acamprosate on alcohol-induced NGFI-A expression in mouse brain.

Authors:  Jeanette Lindholm; Marc Guitart-Masip; Homa Hassankhali; Sara Landgren; Camille Nicoleau; Lydia Giménez-Llort; Lars Terenius; Sven Ove Ogren; Björn Johansson
Journal:  Neurochem Res       Date:  2008-04-22       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.